2024 World Conference on Lung Cancer (WCLC)

As we wrap-up #WCLC24 we thank everyone that visited our booth and shared the excitement around our new data release on foritinib (SAF-189s) Vs Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC).

About The REMARK study:  

The REMARK study is an Ongoing, Randomized, Open-label, Phase 3 trial that met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in PFS in ALK-TKI naïve NSCLC patients in interim analysis. Median PFS NR vs 13.93 months; HR=0.23, 95%CI：0.14 –0.38, p <0.0001.  

Foritinib showed significant improvement of central nervous system (CNS) efficacy vs crizotinib.

CNS-TTP NR vs 19.32 months; HR=0.04, 95%CI：0.01-0.14，p<0.0001.  

Foritinib showed improvement in overall survival vs crizotinib. Median OS NR vs 24.94 months; HR=0.60, 95%CI：0.30-1.20.

The safety profile of foritinib was as expected with no new findings.  

Stay tuned for new data release at #ESMO24  

#WCLC24 #lungcancer #ALK+ #SCLC #GoHenlius #FOSUNPHARMAUSA

Please contact Nadra Belamri nadra.belamri@fosunpharmausa.com for more info about Fosun Pharma USA